These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 31783037)

  • 1. The role of fit-for-purpose assays within tiered testing approaches: A case study evaluating prioritized estrogen-active compounds in an in vitro human uterotrophic assay.
    Beames T; Moreau M; Roberts LA; Mansouri K; Haider S; Smeltz M; Nicolas CI; Doheny D; Phillips MB; Yoon M; Becker RA; McMullen PD; Andersen ME; Clewell RA; Hartman JK
    Toxicol Appl Pharmacol; 2020 Jan; 387():114774. PubMed ID: 31783037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Screening Chemicals for Estrogen Receptor Bioactivity Using a Computational Model.
    Browne P; Judson RS; Casey WM; Kleinstreuer NC; Thomas RS
    Environ Sci Technol; 2015 Jul; 49(14):8804-14. PubMed ID: 26066997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between the results of in vitro receptor binding assay to human estrogen receptor alpha and in vivo uterotrophic assay: comparative study with 65 selected chemicals.
    Akahori Y; Nakai M; Yamasaki K; Takatsuki M; Shimohigashi Y; Ohtaki M
    Toxicol In Vitro; 2008 Feb; 22(1):225-31. PubMed ID: 17904329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro-to-in vivo extrapolation (IVIVE) by PBTK modeling for animal-free risk assessment approaches of potential endocrine-disrupting compounds.
    Fabian E; Gomes C; Birk B; Williford T; Hernandez TR; Haase C; Zbranek R; van Ravenzwaay B; Landsiedel R
    Arch Toxicol; 2019 Feb; 93(2):401-416. PubMed ID: 30552464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro-in silico-based probabilistic risk assessment of combined exposure to bisphenol A and its analogues by integrating ToxCast high-throughput in vitro assays with in vitro to in vivo extrapolation (IVIVE) via physiologically based pharmacokinetic (PBPK) modeling.
    Lin YJ; Lin Z
    J Hazard Mater; 2020 Nov; 399():122856. PubMed ID: 32937695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incorporating population variability and susceptible subpopulations into dosimetry for high-throughput toxicity testing.
    Wetmore BA; Allen B; Clewell HJ; Parker T; Wambaugh JF; Almond LM; Sochaski MA; Thomas RS
    Toxicol Sci; 2014 Nov; 142(1):210-24. PubMed ID: 25145659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implementing Toxicity Testing in the 21st Century (TT21C): Making safety decisions using toxicity pathways, and progress in a prototype risk assessment.
    Adeleye Y; Andersen M; Clewell R; Davies M; Dent M; Edwards S; Fowler P; Malcomber S; Nicol B; Scott A; Scott S; Sun B; Westmoreland C; White A; Zhang Q; Carmichael PL
    Toxicology; 2015 Jun; 332():102-11. PubMed ID: 24582757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Towards an integrated in vitro strategy for estrogenicity testing.
    Wang S; Aarts JM; de Haan LH; Argyriou D; Peijnenburg AA; Rietjens IM; Bovee TF
    J Appl Toxicol; 2014 Sep; 34(9):1031-40. PubMed ID: 24114741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integration of dosimetry, exposure, and high-throughput screening data in chemical toxicity assessment.
    Wetmore BA; Wambaugh JF; Ferguson SS; Sochaski MA; Rotroff DM; Freeman K; Clewell HJ; Dix DJ; Andersen ME; Houck KA; Allen B; Judson RS; Singh R; Kavlock RJ; Richard AM; Thomas RS
    Toxicol Sci; 2012 Jan; 125(1):157-74. PubMed ID: 21948869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Key learnings from the Endocrine Disruptor Screening Program (EDSP) Tier 1 rodent uterotrophic and Hershberger assays.
    Marty MS; O'Connor JC
    Birth Defects Res B Dev Reprod Toxicol; 2014 Feb; 101(1):63-79. PubMed ID: 24515841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation and Optimization of Pharmacokinetic Models for
    Casey WM; Chang X; Allen DG; Ceger PC; Choksi NY; Hsieh JH; Wetmore BA; Ferguson SS; DeVito MJ; Sprankle CS; Kleinstreuer NC
    Environ Health Perspect; 2018 Sep; 126(9):97001. PubMed ID: 30192161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathway Based Toxicology and Fit-for-Purpose Assays.
    Clewell RA; McMullen PD; Adeleye Y; Carmichael PL; Andersen ME
    Adv Exp Med Biol; 2016; 856():205-230. PubMed ID: 27671724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Comparison of ToxCast Test Results with In Vivo and Other In Vitro Endpoints for Neuro, Endocrine, and Developmental Toxicities: A Case Study Using Endosulfan and Methidathion.
    Silva M; Pham N; Lewis C; Iyer S; Kwok E; Solomon G; Zeise L
    Birth Defects Res B Dev Reprod Toxicol; 2015 Apr; 104(2):71-89. PubMed ID: 26017137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening chemicals for thyroid-disrupting activity: A critical comparison of mammalian and amphibian models.
    Pickford DB
    Crit Rev Toxicol; 2010 Nov; 40(10):845-92. PubMed ID: 20684730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro to in vivo extrapolation for predicting human equivalent dose of phenolic endocrine disrupting chemicals: PBTK model development, biological pathways, outcomes and performance.
    Xie R; Wang X; Xu Y; Zhang L; Ma M; Wang Z
    Sci Total Environ; 2023 Nov; 897():165271. PubMed ID: 37422235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro to in vivo extrapolation for high throughput prioritization and decision making.
    Bell SM; Chang X; Wambaugh JF; Allen DG; Bartels M; Brouwer KLR; Casey WM; Choksi N; Ferguson SS; Fraczkiewicz G; Jarabek AM; Ke A; Lumen A; Lynn SG; Paini A; Price PS; Ring C; Simon TW; Sipes NS; Sprankle CS; Strickland J; Troutman J; Wetmore BA; Kleinstreuer NC
    Toxicol In Vitro; 2018 Mar; 47():213-227. PubMed ID: 29203341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The estrogenic effects of apigenin, phloretin and myricetin based on uterotrophic assay in immature Wistar albino rats.
    Barlas N; Özer S; Karabulut G
    Toxicol Lett; 2014 Apr; 226(1):35-42. PubMed ID: 24487097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Critical review and evaluation of the uterotrophic bioassay for the identification of possible estrogen agonists and antagonists: in support of the validation of the OECD uterotrophic protocols for the laboratory rodent. Organisation for Economic Co-operation and Development.
    Owens JW; Ashby J
    Crit Rev Toxicol; 2002; 32(6):445-520. PubMed ID: 12487363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple receptors shape the estrogen response pathway and are critical considerations for the future of in vitro-based risk assessment efforts.
    Miller MM; McMullen PD; Andersen ME; Clewell RA
    Crit Rev Toxicol; 2017 Aug; 47(7):564-580. PubMed ID: 28675057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using ToxCast to Explore Chemical Activities and Hazard Traits: A Case Study With Ortho-Phthalates.
    Pham N; Iyer S; Hackett E; Lock BH; Sandy M; Zeise L; Solomon G; Marty M
    Toxicol Sci; 2016 Jun; 151(2):286-301. PubMed ID: 26969370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.